Cord Blood Banking Market to Near $50B

The first successful cord blood transplant was performed in 1988 on a five-year-old boy named Matthew Farrow, who was suffering from Fanconi Anemia, a rare and life-threatening blood disorder. The groundbreaking procedure, which used stem cells from his newborn sister's umbilical cord, was conducted in Paris by Dr. Eliane Gluckman, following the pioneering work of Dr. Hal Broxmeyer who discovered hematopoietic stem cells in cord blood. Today, stem cells from cord blood can be used to treat over 85 different diseases, including a range of cancers like leukemias and lymphomas, blood disorders such as sickle cell anemia, and various immune system deficiencies. This has led to more than 40,000 cord blood transplants being performed globally since that first procedure. The market is divided between public and private banks. Public banking is free, with the donated cord blood available to any matching patient in need. Private banking, where families pay to store their baby's cord blood for their own potential use, involves initial fees ranging from approximately $1,500 to $3,000, with annual storage costs between $150 and $300. Leading private cord blood banks in the U.S. include Cord Blood Registry (CBR), which has stored over one million units, Viacord, and Cryo-Cell. These companies are part of an industry that not only stores cord blood but also often preserves cord tissue, which contains a different type of stem cell being researched for its regenerative potential. The future of cord blood applications is being actively explored in hundreds of clinical trials. Researchers are investigating the use of cord blood stem cells for treating neurological conditions like cerebral palsy, autism, and Alzheimer's disease, as well as for repairing damaged heart tissue and managing autoimmune disorders.